Full Press Release Details
Rafael Holdings Announces Patent Licensing Agreement
with MIT for "Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease"
License of the MIT patent strengthens Rafael's
intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer's
NEWARK, NJ - April 22, 2026 (GLOBE NEWSWIRE)
- Rafael Holdings, Inc. (NYSE: RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing
agreement with Massachusetts Institute of Technology ("MIT") covering U.S. Patent No.12285440. This license covers the use
of cyclodextrins in patients with Alzheimer's Disease (AD) who carry an ApoE4 genetic mutation, strengthening the company's intellectual
property portfolio around Trappsol Cyclo in this important AD patient population.
The ApoE4 gene variant is estimated to be present
in 50-70% of patients with AD and is believed to be a key risk factor in the development early onset sporadic AD. Dysregulated cholesterol
metabolism is believed to contribute to amyloid and tau pathology, especially in those patients with the ApoE4 gene variant, which has
been shown to accelerate AD as it is the key lipids/cholesterol transporter in the brain.
The established mechanism of action (MOA) for
Trappsol Cyclo could have a direct impact in ApoE4 positive patients as it has been shown to improve cholesterol
transport between central nervous system (CNS) cells. Preclinical data suggest Trappsol Cyclo can improve delivery
of cholesterol between CNS cells, reduce tau-pathology and improve learning/memory in mice.
"Securing this exclusive license from MIT
represents a transformative milestone for our company and greater potential positive news for the millions of patients and their families
affected by Alzheimer's disease. By combining the results of MIT's world-class foundational research with our clinical development expertise,
we are well positioned to accelerate a potential breakthrough that addresses the underlying pathology of this devastating condition. This
agreement underscores our commitment to pursuing the highest caliber of innovation to deliver life-changing therapies to patients in need,"
said Howard Jonas, CEO, Executive Chairman and Chairman of the Board of Rafael Holdings.
Phase 3 results from Transport NPC due in calendar Q3, 2026, we're excited by Trappsol Cyclo 's
potential across multiple disease areas. Our NPC1 phase 3 study is the largest ever conducted in
patients with NPC, yielding crucial clinical and safety data needed to advance the treatment paradigm for patients and families dealing
with NPC " said Joshua Fine, COO of Rafael Holdings.
About Rafael Holdings, Inc.
Rafael Holdings, Inc. is a biotechnology company
that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices.
Our lead candidate is Trappsol Cyclo ,which is being evaluated in clinical trials for the potential treatment of
Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and
early-stage pharmaceutical development companies and an orthopedic-focused medical device company. Our lead candidate, Trappsol
Cyclo is the subject of an ongoing pivotal Phase 3 clinical trial.
Forward Looking Statements
This press release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding
our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding
the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs.
These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that
may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption "Risk Factors"
in our Annual Report on Form 10-K for the year ended July 31, 2025, and our other filings with the SEC. These factors could cause actual
results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking
statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.